UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

~~the~~ Securities Exchange Act of 1934

Date of ~~Report~~report (Date of earliest event reported) ~~April~~May 2210, 2011

INSPIRE PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in ~~its charter~~Charter)

Delaware	~~001~~000-~~31577~~31135	04-3209022
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
8081 Arco Corporate Drive, Suite 400, Raleigh, North Carolina		27703-8466
(Address of Principal Executive Offices)		(Zip Code)

8081 Arco Corporate Drive, Suite 400, Raleigh, North Carolina (Address of Principal Executive Offices) 27617 (Zip Code)

Registrant’s telephone number, including area code (919) 941-9777

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 82.0102 ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On ~~April~~ May 2210, 2011, Inspire Pharmaceuticals, Inc. ~~(the~~issued ~~“Company”) announced in~~ a press release itannouncing ~~was~~summary ~~indefinitely~~financial ~~postponing~~results ~~its Annual Meeting of Stockholders (the “Annual Meeting”) which had been scheduled~~ for ~~May 6, 2011, due to~~ the ~~recently~~fiscal ~~announced~~quarter ~~Agreement~~ended ~~and Plan of Merger, dated April~~March 531, 2011~~, by and among the Company, Merck & Co~~., ~~Inc.~~The ~~(“Merck”),~~press ~~and~~release ~~Monarch~~issued ~~Transaction~~in ~~Corp. (“Monarch”), a wholly owned subsidiary of~~connection ~~Merck~~with ~~pursuant~~such toannouncement ~~which Merck, through Monarch, has commenced a tender offer to purchase all of the outstanding shares of the Company’s common stock. A copy of the press release~~ is attached hereto as Exhibit 99.1.

InThe information in this Current Report on Form 8-K, including the accompanying ~~event~~exhibit, itis ~~becomes~~being ~~necessary~~furnished toand ~~hold~~shall not be deemed “filed” for purposes of Section 18 of the ~~Annual~~Securities ~~Meeting~~Exchange ~~later~~Act ~~this~~of ~~year~~1934, as amended (the ~~Company~~“Exchange ~~will~~Act”), ~~inform~~or ~~stockholders~~otherwise ofsubject to the ~~new~~liabilities ~~meeting~~of that ~~date~~section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
No.		Description
99.1		Press ~~Release~~release dated ~~April~~May 2210, 2011.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, ~~as amended,~~ the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Inspire Pharmaceuticals, Inc.

By:		/s/ Joseph M. Spagnardi
		Joseph M. Spagnardi,
		Senior Vice President, General Counsel and Secretary

Dated: ~~April~~May 2210, 2011

EXHIBIT INDEX

Exhibit No.		Description
No.		Description
99.1		Press ~~Release~~release dated ~~April~~May 2210, 2011.

Filing Compare · INSPIRE PHARMACEUTICALS INC